Ross Mabon

USPTO Granted Patents = 22 (Patent Applications = 10)

CIPO Patents = 9 (Patent Applications = 3)

EPO Patents = 6 (Patent Applications = 13)

Average Co-Inventor Count = 5.4

ph-index = 4

Forward Citations = 34(Granted Patents)

Location History:

Princeton, NJ (US) (2009 - 2013)
Lambertville, NJ (US) (2013 - 2017)
Whitehall, PA (US) (2019 - 2024)

Company Filing History:

10 out of 86

Lexicon Pharmaceuticals, Inc.

patents

6 out of 369

Exxonmobil Technology and Engineering Company

patents

4 out of 1,780

Exxonmobil Research and Engineering Company

patents

4. 2 out of 4,554

California Institute of Technology

patents

Years Active: 2009-2025

Loading Chart...

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12466738 - Intramolecular pi-stacking structure directing agents and molecular sieves synthesized therefrom (2025-11-11),

2. 12398043 - Zeolite syntheses using diquaternary structure directing agents (2025-08-26),

3. 12161990 - EMM-41 composition, methods of making and uses thereof (2024-12-10),

4. 12037255 - Zeolite syntheses using diquaternary structure directing agents (2024-07-16),

5. 11597882 - Co-processing of biomass oil in coker (2023-03-07),

6. 11453841 - Functionalized branched alcohols as non-ionic sugar surfactants (2022-09-27),

7. 11292756 - Surfactant performance through carbon chain extension and lower branching (2022-04-05),

8. 10710889 - EMM-31 materials and processes and uses thereof (2020-07-14),

9. 10597300 - EMM-28, a novel synthetic crystalline material, its preparation and use (2020-03-24),

10. 10252918 - EMM-28, a novel synthetic crystalline material, its preparation and use (2019-04-09),

11. 9624238 - 4H-thieno[3,2-C]chromene-based inhibitors of Notum Pectinacetylesterase and methods of their use (2017-04-18),

12. 9365602 - Sodium glucose co-transporter inhibitors and methods of their use (2016-06-14),

13. 8507672 - Substituted pyrrolo[2,3-d]pyrimidines as LIM kinase 2 inhibitors (2013-08-13),

14. 8476413 - Sulfanyl-tetrahydropyran-based compounds and methods of their use (2013-07-02),

15. 8450332 - LIMK2 inhibitors, compositions comprising them, and methods of their use (2013-05-28),

Title: Innovations by Ross Mabon: A Journey Through Patents and Collaborations

Introduction

Ross Mabon, an esteemed inventor based in Princeton, NJ, has made significant contributions to the field of pharmaceuticals with a portfolio of 12 patents. His innovative work focuses on the development of compounds aimed at treating various diseases and disorders, showcasing his dedication to advancing medical science.

Latest Patents

Among his latest patents is the invention of 4H-thieno[3,2-C]chromene-based inhibitors of Notum Pectinacetylesterase. This patent details compounds that can inhibit Notum Pectinacetylesterase and outlines methods for their use to treat diseases and disorders affecting bone health. Another noteworthy patent involves sodium glucose co-transporter inhibitors. This includes sulfanyl-tetrahydropyran-based compounds and their pharmaceutical compositions, which demonstrate potential in treating diabetes and obesity.

Career Highlights

Throughout his career, Ross Mabon has been associated with several notable organizations. He has contributed his expertise to Lexicon Pharmaceuticals, Inc. and the California Institute of Technology. His innovative research in these settings has propelled advancements in the pharmaceutical industry, particularly concerning his specialized areas of study.

Collaborations

Ross Mabon has had the privilege of working alongside talented individuals such as Bryce Alden Harrison and David Brent Rawlins. These collaborations have fostered a dynamic exchange of ideas and innovations, further enriching his contributions to the field.

Conclusion

Ross Mabon's dedication to innovation in pharmaceuticals reflects his commitment to improving health outcomes through research and invention. His extensive patent portfolio serves as a testament to his role as a leading inventor in the industry, paving the way for future developments in medical treatments.

This text is generated by artificial intelligence and may not be accurate.